CD47/SIRPA-BLOCKING AGENT ALX148
High Grade B-Cell Lymphoma
M.D. Anderson Cancer Centerprotein_peptidePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
84 Active assets in the High Grade B-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Isocyclophosphamide University of California, Davis | Phase 3 | BB |
Etoposide University of Washington | Phase 3 | BB |
Prednisone National Cancer Institute (NCI) | Phase 3 | BB |
Adriamycin National Cancer Institute (NCI) | Phase 3 | BB |
Vincristine Sulfate National Cancer Institute (NCI) | Phase 2/3 | BB |
View all 50 →
Same molecule, other indications
CD47/SIRPA-BLOCKING AGENT ALX148 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →